Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q3 2021 · 10-Q
Revenue$1.20M$1.20M+0.8% vs Q3 2020 Net Income-$42.40M-$42.40MN/M vs Q3 2020 EPS Diluted-$0.05-$0.05N/M vs Q3 2020 Operating Income-$42,181,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$46,834,000N/M Margins · derivedOperating margin-3506.3%−499.2 pt vs Q3 2020
Net margin-3524.6%−554.6 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 4, 2021 · 35 d after period end